Mechanistically, KLF4 has been shown to inhibit HCC progression through the regulation of signaling pathways such as KLF4-pcadherin-GSK-3β and KLF4-CD9/CD81-JNK [9,10]. Here, GSK3B is linked to hepatocellular carcinoma.